Investigation of Verrica Pharmaceuticals Inc. Continues by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. – VRCA

Former Louisiana Attorney General Charles C. Foti, Jr., Esq., a partner in the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF is continuing its investigation of Verrica Pharmaceuticals Inc. (NasdaqGM: VRCA).

In December 2020, the Company submitted a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) seeking regulatory approval of its lead product, VP-102, or YCANTH, for the treatment of molluscum contagiosum, a skin disease. On September 20, 2021, the Company announced receipt of a Complete Response Letter (“CRL”) relating to deficiencies in its contract manufacturer’s facility. In November 2021, the Company resubmitted the NDA, claiming: “[t]The resubmission addresses the successful remediation of inspection deficiencies” at the manufacturing facility. Then, on May 24, 2022, the company announced receipt of another Complete Response Letter regarding the VP-102 NDA, citing “deficiencies identified during a general re-inspection of Sterling Pharmaceuticals Services, LLC (Sterling), the contract manufacturing organization (CMO) that manufactures Verrica’s drug product in bulk packages.”